Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 30, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:July 30, 2019Completed
Condition(s):Multiple MyelomaLast Updated:October 18, 2022Completed
Condition(s):Multiple MyelomaLast Updated:February 2, 2022Terminated
Condition(s):Multiple MyelomaLast Updated:July 17, 2019Completed
Condition(s):Multiple Myeloma in RelapseLast Updated:September 5, 2021Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:August 29, 2013Completed
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 6, 2023Completed
Condition(s):Multiple MyelomaLast Updated:March 2, 2022Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 24, 2022Completed
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:July 7, 2022Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.